Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease

Diagnostic and Statistical Manual of Mental Disorders

Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,841 · see citing works

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*

Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works

Intracellular amyloid-β in Alzheimer's disease

LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: Implications for Alzheimer’s disease therapeutics

Roberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · see citing works

β-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease

Fukumoto, H. (2002) · Archives of Neurology · doi:10.1001/archneur.59.9.1381 · Cited by 694 · see citing works

CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study

Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

Report of the second dementia with Lewy body international workshop

McKeith, I. G., Perry, E. K., & Perry, R. H. (1999) · Neurology · doi:10.1212/wnl.53.5.902 · Cited by 464 · see citing works

Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice

Dominguez, D. I., Tournoy, J., Hartmann, D., Huth, T., Cryns, K., Deforce, S., Serneels, L., Espuny-Camacho, I., Marjaux, E., Craessaerts, K., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505249200 · Cited by 359 · see citing works

Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment

Zhong, Z., Ewers, M., Teipel, S., Bürger, K., Wallin, A., Blennow, K., He, P., McAllister, C., Hampel, H., & Shen, Y. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.718 · Cited by 206 · see citing works

Differential regulation of BACE1 promoter activity by nuclear factor‐κB in neurons and glia upon exposure to β‐amyloid peptides

Bourne, K. Z., Ferrari, D. C., Lange‐Dohna, C., Roßner, S., Wood, T. G., & Perez-Polo, J. R. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21252 · Cited by 188 · see citing works

Lipocalin-type prostaglandin D synthase/β-trace is a major amyloid β-chaperone in human cerebrospinal fluid

Kanekiyo, T., Ban, T., Aritake, K., Huang, Z., Qu, W., Okazaki, I., Mohri, I., Murayama, S., Ozono, K., Taniike, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701585104 · Cited by 147 · see citing works

Increased CSF-BACE 1 activity is associated with ApoE-ε4 genotype in subjects with mild cognitive impairment and Alzheimer's disease

Ewers, M., Zhong, Z., Bürger, K., Wallin, A., Blennow, K., Teipel, S. J., Shen, Y., & Hampel, H. (2008) · Brain · doi:10.1093/brain/awn034 · Cited by 119 · see citing works

Increased β‐Secretase activity in cerebrospinal fluid of Alzheimer's disease subjects

Holsinger, R. M. D., McLean, C., Collins, S. J., Masters, C. L., & Evin, G. M. (2004) · Annals of Neurology · doi:10.1002/ana.20144 · Cited by 96 · see citing works

CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias

Holsinger, R. M. D., Lee, J. S., Boyd, A., Masters, C. L., & Collins, S. J. (2006) · Neurology · doi:10.1212/01.wnl.0000229925.52203.4c · Cited by 77 · see citing works

Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease

Johnston, J. A., Liu, W. W., Todd, S., Coulson, D. T. R., Murphy, S., Irvine, G. B., & Passmore, A. P. (2005) · Biochemical Society Transactions · doi:10.1042/bst20051096 · Cited by 76 · see citing works

Aspects of β-Amyloid as a Biomarker for Alzheimer's Disease

Andréasson, U., Portelius, E., Andersson, M. E., Blennow, K., & Zetterberg, H. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.1.59 · Cited by 74 · see citing works

Detection of a Soluble Form of BACE-1 in Human Cerebrospinal Fluid by a Sensitive Activity Assay

Verheijen, J. H., Huisman, L. G. M., van Lent, N., Neumann, U., Paganetti, P., Hack, C. E., Bouwman, F. H., Lindeman, J. H. N., Bollen, E. L. E. M., & Hanemaaijer, R. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.066720 · Cited by 67 · see citing works

Novel mutations introduced at the β-site of amyloid β protein precursor enhance the production of amyloid β peptide by BACE1 in vitro and in cells

Shi, X.-P., Tugusheva, K., Bruce, J. E., Lucka, A., Chen-Dodson, E., Hu, B., Wu, G.-X., Price, E. A., Register, R. B., Lineberger, J. E., et al. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-7207 · Cited by 36 · see citing works

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works

The β-Secretase BACE1 in Alzheimer’s Disease

Hampel, H., Vassar, R., De Strooper, B., Hardy, J., Willem, M., Singh, N., Zhou, J., Yan, R., Vanmechelen, E., De Vos, A., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.02.001 · Cited by 694 · see citing works

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

Hampel, H. J., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 630 · see citing works

A Phase II Trial of Tideglusib in Alzheimer's Disease

Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · see citing works

Current state of Alzheimer’s fluid biomarkers

Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works

Amyloid biomarkers in Alzheimer's disease

Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · see citing works

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., & Drago, F. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04134.x · Cited by 322 · see citing works

MicroRNA-193b is a regulator of amyloid precursor protein in the blood and cerebrospinal fluid derived exosomal microRNA-193b is a biomarker of Alzheimer’s disease

Liu, C., Song, J., Zhang, Y., & Wang, P. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2484 · Cited by 221 · see citing works

Fluid biomarkers in Alzheimer’s disease – current concepts

Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Idiopathic normal-pressure hydrocephalus

Jeppsson, A., Zetterberg, H., Blennow, K., & Wikkelsø, C. (2013) · Neurology · doi:10.1212/wnl.0b013e31828c2fda · Cited by 183 · see citing works

Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease

Paris, D., Ganey, N. J., Laporte, V., Patel, N. S., Beaulieu‐Abdelahad, D., Bachmeier, C. J., March, A., Ait‐Ghezala, G., & MULLAN, M. J. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-17 · Cited by 169 · see citing works

A novel pathway for amyloid precursor protein processing

Portelius, E., Price, E. A., Brinkmalm, G., Stiteler, M., Olsson, M., Persson, R., Brinkmalm, A., Zetterberg, H., Simon, A. J., & Blennow, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.002 · Cited by 169 · see citing works

Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163 · see citing works

BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease.

Barão, S., Moechars, D., Lichtenthaler, S., & de Strooper, B. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.01.003 · Cited by 161 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives

McGrowder, D. A., Miller, F. G., Vaz, K., Nwokocha, C. R., Wilson-Clarke, C. F., Anderson, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167 · see citing works

Biological markers of amyloid β-related mechanisms in Alzheimer's disease

Hampel, H. J., Shen, Y., Walsh, D. M., Aisen, P. S. S., Shaw, L. M., Zetterberg, H., Trojanowski, J. Q., & Blennow, K. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.024 · Cited by 159 · see citing works

Biomarkers for Alzheimer’s Disease Early Diagnosis

Ausó, E., Gómez‐Vicente, V., & Esquiva, G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030114 · Cited by 149 · see citing works

Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

Pathak, N., Vimal, S. K., Tandon, I., Agrawal, L., Cao, H., & Bhattacharyya, S. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00800-w · Cited by 149 · see citing works

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection

Gisslén, M., Krut, J. J., Andréasson, U., Blennow, K., Cinque, P. M., Brew, B. J., Spudich, S., Hagberg, L., Rosengren, L., Price, R. W., et al. (2009) · BMC Neurology · doi:10.1186/1471-2377-9-63 · Cited by 147 · see citing works

Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design

van Rossum, I. A., Vos, S. J. B., Handels, R. L. H., & Visser, P. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091606 · Cited by 143 · see citing works

Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson’s Disease

Trupp, M., Jonsson, P., Öhrfelt, A., Zetterberg, H., Obudulu, O., Malm, L., Wuolikainen, A., Linder, J., Möritz, T., Blennow, K., et al. (2014) · Journal of Parkinson s Disease · doi:10.3233/jpd-140389 · Cited by 140 · see citing works

Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 138 · see citing works

Increased plasma beta-secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment

Shen, Y., Wang, H., Sun, Q., Yao, H., Keegan, A. P., Mullan, M., Wilson, J., Lista, S., Leyhe, T., Laske, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.007 · Cited by 123 · see citing works

Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease

Pera, M., Alcolea, D. A., Sánchez‐Valle, R., Guardia‐Laguarta, C., Colom‐Cadena, M., Badiola, N., Suárez‐Calvet, M., Lladó, A., Barrera-Ocampo, A. A., Falla, D. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1062-9 · Cited by 122 · see citing works

Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment

Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S. M., & Hansson, O. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.012 · Cited by 120 · see citing works

MicroRNA-135a and -200b, potential Biomarkers for Alzheimer׳s disease, regulate β secretase and amyloid precursor protein

Liu, C., Wang, J., Li, L., Xue, L., Zhang, Y., & Wang, P. (2014) · Brain Research · doi:10.1016/j.brainres.2014.04.026 · Cited by 117 · see citing works

Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection

Peterson, J. J., Gisslén, M., Zetterberg, H., Fuchs, D., Shacklett, B. L., Hagberg, L., Yiannoutsos, C. T., Spudich, S., & Price, R. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0116081 · Cited by 115 · see citing works

Upcoming Candidate Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Fagan, A. M., & Perrin, R. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.42 · Cited by 115 · see citing works

Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus

Pyykkö, O. T., Lumela, M., Rummukainen, J. K., Nerg, O., Seppälä, T. T., Herukka, S., Koivisto, A. M., Alafuzoff, I. I., Puli, L., Savolainen, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091974 · Cited by 114 · see citing works

Amyloid β and APP as biomarkers for Alzheimer’s disease

Zetterberg, H., Blennow, K., & Hanse, E. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.08.002 · Cited by 113 · see citing works

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: Randomized, double-blind, placebo-controlled study

Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112 · see citing works

A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease

Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111 · see citing works

miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease

Ansari, A., Maffioletti, E., Milanesi, E., Marizzoni, M., Frisoni, G. B., Blin, O., Richardson, J. C., Bordet, R., Forloni, G., Gennarelli, M., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.06.005 · Cited by 111 · see citing works

Cerebrospinal fluid biomarkers of white matter lesions – cross‐sectional results from the LADIS study

Jonsson, M. A. G., Zetterberg, H., van Straaten, E. C. W., LIND, K., Syversen, S., Edman, Å., Blennow, K., Rosengren, L., Pantoni, L., Inzitari, D., et al. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02808.x · Cited by 111 · see citing works

Biomarkers in Sporadic and Familial Alzheimer’s Disease

Lista, S., O’Bryant, S. E., Blennow, K., Dubois, B., Hugon, J., Zetterberg, H., & Hampel, H. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-143006 · Cited by 106 · see citing works

MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer’s disease

Liu, C., Wang, J., Li, L., & Wang, P. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1780 · Cited by 106 · see citing works

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer’s Disease

Hillen, H. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01154 · Cited by 106 · see citing works

Biomarker-based dissection of neurodegenerative diseases

Olsson, B., Zetterberg, H., Hampel, H. J., & Blennow, K. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.006 · Cited by 96 · see citing works

CSF biomarkers distinguish idiopathic normal pressure hydrocephalus from its mimics

Jeppsson, A., Wikkelsø, C., Blennow, K., Zetterberg, H., Constantinescu, R., Remes, A. M., Herukka, S., Rauramaa, T. H., Nägga, K., Leinonen, V., et al. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320826 · Cited by 95 · see citing works

Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.

Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · Europe PMC (PubMed Central) · Cited by 92 · see citing works

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Villa, C., Lavitrano, M., Salvatore, E., & Combi, R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030061 · Cited by 89 · see citing works

Regulation of alpha-secretase ADAM10 expression and activity

Endres, K., & Fahrenholz, F. (2011) · Experimental Brain Research · doi:10.1007/s00221-011-2885-7 · Cited by 79 · see citing works

Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid

Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Chaulet, C., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.022 · Cited by 78 · see citing works

Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer’s disease

Milà‐Alomà, M., Suárez‐Calvet, M., & Molinuevo, J. L. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419888819 · Cited by 78 · see citing works

Update on Biomarkers For Amyloid Pathology in Alzheimer’s Disease

Ashton, N. J., Schöll, M., Heurling, K., Gkanatsiou, E., Portelius, E., Höglund, K., Brinkmalm, G., Hye, A., Blennow, K., & Zetterberg, H. (2018) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0433 · Cited by 75 · see citing works

Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer’s Disease

Rosén, C., Andréasson, U., Mattsson, N., Marcusson, J. O., Minthon, L., Andreasen, N., Blennow, K., & Zetterberg, H. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8171-4 · Cited by 72 · see citing works

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease

Prvulovic, D., & Hampel, H. J. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.087 · Cited by 73 · see citing works

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population

Johansson, P., Mattsson, N., Hansson, O., Wallin, A., Johansson, J.-O., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101878 · Cited by 71 · see citing works

CSF Biomarkers in the Early Diagnosis of Mild Cognitive Impairment and Alzheimer’s Disease

Papaliagkas, V. T., Kalinderi, K., Vareltzis, P. K., Μoraitou, D., Papamitsou, T., & Chatzidimitriou, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108976 · Cited by 73 · see citing works

BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System

Mattsson, N., Rajendran, L., Zetterberg, H., Gustavsson, M. K., Andréasson, U., Olsson, M., Brinkmalm, G., Lundkvist, J., Jacobson, L. H., Perrot, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031084 · Cited by 70 · see citing works

Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease

Wu, G., Sankaranarayanan, S., Wong, J., Tugusheva, K., Michener, M. S., Shi, X., Cook, J. J., Simon, A. J., & Savage, M. J. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23122 · Cited by 68 · see citing works

Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers

Neselius, S., Zetterberg, H., Blennow, K., Marcusson, J. O., & Brisby, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081249 · Cited by 68 · see citing works

CSF Biomarkers

Mattsson, N., Blennow, K., & Zetterberg, H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04944.x · Cited by 68 · see citing works

Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools

Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 64 · see citing works

β‐Secretase‐1 elevation in aged monkey and Alzheimer’s disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β‐amyloid accumulation

Cai, Y., Xiong, K., Zhang, X., Cai, H., Luo, X., Feng, J., Clough, R. W., Struble, R. G., Patrylo, P. R., Chu, Y., et al. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07376.x · Cited by 64 · see citing works

BACE2 Expression Increases in Human Neurodegenerative Disease

Holler, C. J., Webb, R. L., Laux, A. L., Beckett, T. L., Niedowicz, D. M., Ahmed, R. R., Liu, Y., Simmons, C. R., Dowling, A. L. S., Spinelli, A., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.034 · Cited by 63 · see citing works

Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism

Mattsson, N., Bremell, D., Anckarsäter, R., Blennow, K., Anckarsäter, H. S., Zetterberg, H., & Hagberg, L. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-51 · Cited by 64 · see citing works

Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease

Ewers, M., Cheng, X., Zhong, Z., Nural, H. F., Walsh, C., Meindl, T., Teipel, S. J., Buerger, K., He, P., Shen, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-091153 · Cited by 58 · see citing works

Serum beta-secretase 1 (BACE1) activity as candidate biomarker for late-onset Alzheimer’s disease

Cervellati, C., Trentini, A., Rosta, V., Passaro, A., Bosi, C., Sanz, J. M., Bonazzi, S., Pacifico, S., Seripa, D., Valacchi, G., et al. (2019) · GeroScience · doi:10.1007/s11357-019-00127-6 · Cited by 58 · see citing works

Paper-Based Platform with an In Situ Molecularly Imprinted Polymer for β-Amyloid

Pereira, M. V., Marques, A. C., Oliveira, D., Martins, R., Moreira, F. T. C., Sales, M. G. F., & Fortunato, E. M. C. (2020) · ACS Omega · doi:10.1021/acsomega.0c00062 · Cited by 57 · see citing works

Soluble Amyloid Precursor Protein 770 Is Released from Inflamed Endothelial Cells and Activated Platelets

Kitazume, S., Yoshihisa, A., Yamaki, T., Oikawa, M., Tachida, Y., Ogawa, K., Imamaki, R., Hagiwara, Y., Kinoshita, N., Takeishi, Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.398578 · Cited by 56 · see citing works

Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease

Bekris, L. M., Galloway, N. M., Millard, S. P., Lockhart, D., Li, G., Galasko, D. R., Farlow, M. R., Clark, C. M., Quinn, J. F., Kaye, J. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.020 · Cited by 52 · see citing works

Systems Approach to Neurodegenerative Disease Biomarker Discovery

Lausted, C. G., Lee, I., Zhou, Y. F., Qin, S., Sung, J., Price, N. D., Hood, L., & Wang, K. (2013) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135928 · Cited by 52 · see citing works

Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls

Rolstad, S., Jakobsson, J., Sellgren, C. M., Ekman, C. J., Blennow, K., Zetterberg, H., Pålsson, E., & Landén, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127100 · Cited by 52 · see citing works

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 52 · see citing works

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid

Selnes, P., Blennow, K., Zetterberg, H., Grambaitė, R., Rosengren, L., Johnsen, L., Stenset, V. T. V., & Fladby, T. (2010) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-7-10 · Cited by 52 · see citing works

The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease

Vos, A. D., Struyfs, H., Jacobs, D., Fransén, E., Klewansky, T., Roeck, E. E. D., Robberecht, C., Broeckhoven, C. V., Duyckaerts, C. J., Engelborghs, S., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160227 · Cited by 52 · see citing works

Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function

Zhu, K., Peters, F., Filser, S., & Herms, J. W. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.04.022 · Cited by 50 · see citing works

Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg

Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 51 · see citing works

Levels of ADAM10 are reduced in Alzheimer’s disease CSF

Sogorb‐Esteve, A., García‐Ayllón, M., Gobom, J., Alom, J., Zetterberg, H., Blennow, K., & Sáez‐Valero, J. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1255-9 · Cited by 50 · see citing works

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease

Johansson, P., Almqvist, E. G., Johansson, J.-O., Mattsson, N., Hansson, O., Wallin, A., Blennow, K., Zetterberg, H., & Svensson, J. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.10.012 · Cited by 48 · see citing works

Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes

Bech, S., Hjermind, L. E., Salvesen, L., Nielsen, J. E., Heegaard, N. H. H., Jørgensen, H. L., Rosengren, L., Blennow, K., Zetterberg, H., & Winge, K. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.08.012 · Cited by 47 · see citing works

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease

Brinkmalm, G., Brinkmalm, A., Bourgeois, P., Persson, R., Hansson, O., Portelius, E., Mercken, M. H., Andréasson, U., Parent, S., Lipari, F., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.03.019 · Cited by 47 · see citing works

Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer’s Disease

Rani, S., Dhar, S. B., Khajuria, A., Gupta, D., Jaiswal, P. K., Singla, N., Kaur, M., Singh, G., & Barnwal, R. P. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01330-y · Cited by 48 · see citing works

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future

Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G. G., & Emanuele, E. (2011) · Neurodegenerative Diseases · doi:10.1159/000327756 · Cited by 44 · see citing works

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

Þórðardóttir, S., Ståhlbom, A. K., Almkvist, O., Thonberg, H., Eriksdotter, M., Zetterberg, H., Blennow, K., & Graff, C. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0234-1 · Cited by 43 · see citing works

Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer’s disease patients

Bram, J. M. D. F., Talib, L. L., Joaquim, H. P. G., Sarno, T. A., Gattaz, W. F., & Forlenza, O. V. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0905-3 · Cited by 43 · see citing works

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification

Hampel, H. J., Lista, S., Vanmechelen, E., Zetterberg, H., Giorgi, F. S., Galgani, A., Blennow, K., Caraci, F., Das, B., Yan, R., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00686-3 · Cited by 42 · see citing works

Early risk assessment for Alzheimer's disease

Carrillo, M. C., Blackwell, A. D., Hampel, H. J., Lindborg, J., Sperling, R. A., Schenk, D., Sevigny, J., Ferris, S. H., Bennett, D. A., Craft, S., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.01.019 · Cited by 42 · see citing works

Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

Perneczky, R., Alexopoulos, P., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.006 · Cited by 41 · see citing works

MiR-16 attenuates β-amyloid-induced neurotoxicity through targeting β-site amyloid precursor protein-cleaving enzyme 1 in an Alzheimer’s disease cell model

Zhong, Z., Yuan, K., Tong, X., Hu, J., Song, Z., Zhang, G., Fang, X., & Zhang, W. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001118 · Cited by 41 · see citing works

Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients

Lukkarinen, H., Jeppsson, A., Wikkelsø, C., Blennow, K., Zetterberg, H., Constantinescu, R., Remes, A. M., Herukka, S., Hiltunen, M. O., Rauramaa, T. H., et al. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-022-00309-z · Cited by 41 · see citing works

Dysregulation and Diagnostic Potential of microRNA in Alzheimer’s Disease

Pan, Y., Liu, R., Terpstra, E. J. M., Wang, Y., Qiao, F., Wang, J., Tong, Y., & Pan, B. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150451 · Cited by 38 · see citing works

Early biomarkers for post-stroke cognitive impairment

Qian, L., Ding, L., Cheng, L., Zhu, X., Zhao, H., Jin, J., Guan, D.-N., Zhang, B., Chen, X., & Xu, Y. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6465-y · Cited by 40 · see citing works

Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers

Perneczky, R., Alexopoulos, P., & Kurz, A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.10.001 · Cited by 40 · see citing works

Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease

Buchhave, P., Janciauskiene, S. M., Zetterberg, H., Blennow, K., Minthon, L., & Hansson, O. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.091 · Cited by 39 · see citing works

CNS Amyloid- , Soluble APP- and - Kinetics during BACE Inhibition

Zakaria, J. A. D., Michener, M. S., Wu, G., Patterson, B. W., Chott, R. C., Ovod, V., Pyatkivskyy, Y., Wildsmith, K. R., Kasten, T. L., Mathers, P. D., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.0540-14.2014 · Cited by 39 · see citing works

A new generation of AD biomarkers: 2019 to 2021

Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 34 · see citing works

APLP1 is endoproteolytically cleaved by γ-secretase without previous ectodomain shedding

Schauenburg, L., Liebsch, F., Eravci, M., Mayer, M., Weise, C., & Multhaup, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19530-8 · Cited by 36 · see citing works

White matter changes in familial Alzheimer's disease

Li, X., Westman, E., Ståhlbom, A. K., Thordardottir, S., Almkvist, O., Blennow, K., Wahlund, L., & Graff, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12352 · Cited by 34 · see citing works

Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI)

Bermejo‐Bescós, P., Martín‐Aragón, S., Jiménez‐Aliaga, K., Benedı́, J., Felici, E., Gil, P., Ribera, J. M., & Villar, A. M. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1039-7 · Cited by 34 · see citing works

Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex

Wu, G., Sankaranarayanan, S., Hsieh, S., Simon, A. J., & Savage, M. J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22618 · Cited by 34 · see citing works

Partial reduction of amyloid β production by β-secretase inhibitors does not decrease synaptic transmission

Şatır, T. M., Agholme, L., Karlsson, A., Karlsson, M., Karila, P., Illes, S., Bergström, P., & Zetterberg, H. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00635-0 · Cited by 33 · see citing works

Cerebrospinal fluid biomarkers in cardiac arrest survivors

Rosén, C., Rosén, H., Andréasson, U., Bremell, D., Bremler, R., Hagberg, L., Rosengren, L., Blennow, K., & Zetterberg, H. (2013) · Resuscitation · doi:10.1016/j.resuscitation.2013.10.032 · Cited by 32 · see citing works

BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants

Timmers, M., Barão, S., Broeck, B. V., Tesseur, I. C., Slemmon, J., Waepenaert, K. D., Bogert, J., Shaw, L. M. J., Engelborghs, S., Moechars, D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160829 · Cited by 32 · see citing works

CSF Presenilin-1 complexes are increased in Alzheimer’s disease

García‐Ayllón, M., Campanari, M., Brinkmalm, G., Rábano, A., Alom, J., Saura, C. A., Andreasen, N., Blennow, K., & Sáez‐Valero, J. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-46 · Cited by 31 · see citing works

Search for biomarkers of Alzheimer‘s disease: Recent insights, current challenges and future prospects

Králová, K., Fousková, M., Habartová, L., Fišar, Z., Jirák, R., Raboch, J., & Setnička, V. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.002 · Cited by 31 · see citing works

Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid

Alexopoulos, P., Tsolakidou, A. F., Roselli, F., Arnold, A., Grimmer, T., Westerteicher, C., Leante, M. R., Förstl, H., Livrea, P., Kurz, A., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.04.009 · Cited by 30 · see citing works

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics

Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 29 · see citing works

O3‐02–06: Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer's disease

Zetterberg, H., Andréasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.419

Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease

Perneczky, R., Alexopoulos, P., & Initiative, A. D. N. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.006 · Cited by 41 · see citing works

EPA-0190 – Novel upstream markers of amyloid precursor protein processing in the diagnosis and prognosis of alzheimer's disease

Perneczky, R., & Alexopoulos, P. (2014) · European Psychiatry · doi:10.1016/s0924-9338(14)77648-5

S4–01–03: Beta–secretase (BACE1) as a predictor of risk in Alzheimer disease: High levels of BACE1 in cerebrospinal fluid of mild cognitive impairment

Shen, Y., Ewers, M., Teipel, S. J., Büger, K., Citron, M., Wallin, A., Blennow, K., Hager, T., Wang, J., Hampel, H. J., et al. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.265 · Cited by 1 · see citing works

P3‐010: Increased BACE1 activity in CSF of patients with an Alzheimer biomarker profile

Mulder, S. D., Mulder, C., Verheijen, J. H., Scheltens, P., Hack, C. E., Blankenstein, M. A., & Veerhuis, R. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1187